SCHEMBL1623130

SCHEMBL1623130

COc1cccc(C(=O)NC2CCN(c3nc(-c4ccccc4O)nc4cc(C)ccc34)C2)c1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 3/20 0.47
CHEK2 O96017 2/20 0.45
ALDH1A1 P00352 1/20 0.45
TSHR P16473 1/20 0.45
CCNE1 P24864 1/20 0.43
CDK2 P24941 1/20 0.43
LMNA P02545 2/20 0.43
CHEK1 O14757 1/20 0.43
MAPT P10636 3/20 0.43
KDM5A P29375 1/20 0.43
KDM4D Q6B0I6 1/20 0.43
MTNR1A P48039 1/20 0.42
MTNR1B P49286 1/20 0.42
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
CCR3 P51677 1/20 0.41
DRD4 P21917 1/20 0.41
HIF1A Q16665 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1623127 1.00 MCHR1 (0.47) MCHR1CHEK2ALDH1A1TSHRCCNE1
SCHEMBL1622315 0.91 TAS1R3 (0.45) MCHR1CHEK2CCNE1CDK2DRD4
SCHEMBL1622312 0.91 TAS1R3 (0.45) MCHR1CHEK2CCNE1CDK2DRD4
SCHEMBL1622674 0.89 CHEK2 (0.47) MCHR1CHEK2CCNE1CDK2KDM5A
SCHEMBL1622668 0.89 CHEK2 (0.47) MCHR1CHEK2CCNE1CDK2KDM5A
SCHEMBL1623912 0.88 CHEK2 (0.45) MCHR1CHEK2TSHRCCNE1CDK2
SCHEMBL1623915 0.88 CHEK2 (0.45) MCHR1CHEK2TSHRCCNE1CDK2
SCHEMBL4019870 0.88 MCHR1 (0.46) MCHR1ALDH1A1TSHRCCNE1CDK2
SCHEMBL1624439 0.88 CHEK2 (0.49) MCHR1CHEK2ALDH1A1CCNE1CDK2
SCHEMBL1624442 0.88 CHEK2 (0.49) MCHR1CHEK2ALDH1A1CCNE1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8283354-B2 Voltage gated sodium and calcium channel inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-10-09 US disclosed
US-7928107-B2 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-04-19 US disclosed
US-20090312342-A1 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2009-12-17 US disclosed
EP-1784393-B1 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMA (US) 2009-07-01 EP disclosed
US-20060173018-A1 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2006-08-03 US disclosed
WO-2006028904-A9 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMA (US) 2006-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312342-A1 Quinazolines useful as modulators of ion channels KCNQ1, KCNQ2, KCNN3 MCHR1 4109/4885CHEK2 2935/4885ALDH1A1 2907/4885
US-20060173018-A1 Quinazolines useful as modulators of ion channels KCNQ1, KCNQ2, KCNN3 MCHR1 4109/4885CHEK2 2935/4885ALDH1A1 2907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.